# What the Affordable Drug Manufacturing Act Actually Does

This bill creates a new government office inside the Department of Health and Human Services with a specific mission: manufacture prescription drugs that are expensive or hard to find, then sell them at lower prices to compete with private pharmaceutical companies. Think of it as the government becoming a drug manufacturer itself to bring down costs and increase competition in the market.

The Office of Drug Manufacturing would start by producing at least 15 different drugs within the first year, expanding to at least 25 drugs by year three. The bill specifically requires the office to begin manufacturing insulin in all its different forms (pens, vials, pumps, and various types), at least one asthma or COPD inhaler, epinephrine auto-injectors, naloxone (the overdose reversal drug), and at least three different antibiotics. The office can also manufacture the raw ingredients that go into drugs if those ingredients are hard to get or only made by one company. When the office sells these drugs to wholesalers or other buyers, it must price them fairly—considering factors like manufacturing costs, patient access, competition in the market, and what federal health programs pay.

The bill includes some important guardrails to prevent conflicts of interest. Former pharmaceutical industry lobbyists cannot work for this office for six years after they stop lobbying, and senior executives from drug companies that have faced legal settlements or enforcement actions cannot lead the office or work there for six years after those cases conclude. Additionally, after three years of manufacturing a drug, the office must offer to sell the rights to make that drug to private companies willing to keep prices reasonable—if they fail to actually market the drug or raise prices above what the office set, the government takes back the rights and resumes production.

For most people, this bill could mean lower prices on commonly used medications, especially insulin and inhalers that many Americans struggle to afford. It could also help during drug shortages by ensuring the government has the ability to manufacture critical medicines. However, the bill doesn't take effect automatically—Congress would need to approve funding for this new office to actually operate.